Back to results
US 2017/0290905 A1Published application
Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsCindy CASTADO, Steve LABBE, Patrick RHEAULT
Life of this patent
Estimating the term…
Abstract
The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.
Claims37
-2. (canceled)
A Virus-Like Particle (VLP), comprising human rhinovirus capsid proteins VP0, VP1 and VP 3.
-10. (canceled)
(canceled)
(canceled)
-25. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-48. (canceled)
-53. (canceled)
A method for producing rhinoviral VLPs comprising the steps of:
- (a) producing constructs encoding capsid proteins required for the formation of a VLP, wherein each of the capsid proteins is encoded as a fusion protein with a chaperone protein, and
- (b) expressing said constructs in a host cell, and
- (c) lysing said host cells.
(canceled)
-67. (canceled)
Dependencies are inferred from the claim text.